文献速递心力衰竭与心肌病

患者报告结局作为心力衰竭试验终点的深度解读

Patient-Reported Outcomes as End Points in Heart Failure Trials.
PubMed 文献 · Circulation · 2025-04-14

心力衰竭影响全球数千万人,患者报告结局(PRO)在药物和器械评估及指南推荐中日益重要。但PRO评估时机与频率无共识,最小临床重要差异难以确立,传统分析方法易产生统计假象和误读。本文以堪萨斯城心肌病问卷为例深入讨论上述问题,以促进PRO在心力衰竭研究、监管和临床中的应用。

要点

  • PRO在心力衰竭试验中作为终点日益受监管机构和指南重视,但解读困难。
  • PRO评估时机与频率无共识,最小临床重要差异难以确立。
  • 传统PRO分析方法(均值差比较、应答者分析)易产生统计假象和误读。

核心结论

  • 心力衰竭试验中PRO的效应目前难以解读,需解决评估时机、最小临床重要差异和分析方法等问题。

研究设计与样本

  • 本文为深度讨论文章,以堪萨斯城心肌病问卷为例,探讨PRO在心力衰竭研究、监管和临床中的应用问题。

主要发现

  • PRO评估时机与频率无共识,最小临床重要差异难以确立。
  • 传统分析方法如组间均值差比较或应答者分析易产生统计假象和误读。

临床怎么用

  • 促进PRO在心力衰竭研究、监管和临床环境中更规范地使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure is a growing health-care concern affecting tens of millions of individuals globally. Although traditional therapeutic strategies have focused on reducing the risk for hospitalization and mortality, the importance of patient-reported outcomes (PROs) in patients with heart failure is increasingly being recognized. Regulatory agencies consider PROs part of their evaluation of drugs and devices, and professional society guidelines may recommend interventions that improve PROs. However, for several reasons, the effect of interventions on PROs reported in heart failure trials currently is difficult to interpret. There is no consensus on the timing and frequency of PRO assessments. Moreover, it has been difficult to establish a minimal clinically important difference, that is, the minimal change in a PRO score that is meaningful to a patient. In addition, traditional methods of analyzing and reporting PROs such as comparison of mean differences across groups or responder analysis are prone to statistical artifacts and misinterpretation. This article presents an in-depth discussion of these issues, with the Kansas City Cardiomyopathy Questionnaire used as an example, to facilitate the use of PROs in heart failure research, regulatory, and clinical settings.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butler, Usman, Gandotra, et al. Patient-Reported Outcomes as End Points in Heart Failure Trials. Circulation. 2025. PMID: 40228065. doi:10.1161/CIRCULATIONAHA.124.072158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。